Amorepacific (090430) unveiled a goal of 15 trillion Korean won (approximately $11.2 billion) in group revenue by 2035, identifying derma beauty, clinical skincare and hair care as new global growth pillars alongside its existing flagship brands. At its 2026 Investor Day at its headquarters in Yongsan, Seoul, on the 11th, the company said Aestura and Illiyoon would lead derma expansion, while its multi-brand hair-care portfolio includes Ryo, Mise-en-scène (also referred to as Mijang Sen) and Labo-H. Aestura and Illiyoon generated more than 400 billion won (approximately $297.5 million) in combined fiscal 2026 revenue, up 67% year over year, with targets of 500 billion won in fiscal 2027 and 1 trillion won by fiscal 2030. Amorepacific also targets 1 trillion won in fiscal 2030 hair-care revenue and a 14–15% segment operating margin. Its fiscal 2027 targets include 10% consolidated revenue growth and an 11–12% operating margin, with regional growth of 20% in North America and 30% each in EMEA and Japan. Digital channels, consumer data and market-specific insights are central to the strategy. KB Securities maintained a Buy rating and a 190,000-won target in its assessment, while Hana Securities separately maintained a Buy rating and a 170,000-won target.